Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BCDA OTCMKTS:CUBT NYSE:IBIO OTCMKTS:IMUC On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBCDABioCardia$2.01-1.5%$2.07$1.63▼$3.26$11.66M0.85156,199 shs4,373 shsCUBTCurative Biotechnology$0.01-5.6%$0.01$0.00▼$0.03$8.61M0.34119,714 shs30,082 shsIBIOiBio$0.82-4.4%$0.74$0.56▼$6.89$16.16M0.861.52 million shs57,205 shsIMUCEOM Pharmaceutical$0.07+14.1%$0.08$0.01▼$0.21$8.80M0.062,437 shs850 shs7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBCDABioCardia+3.03%+5.15%+4.08%-4.23%-28.92%CUBTCurative Biotechnology-5.56%-24.11%-4.49%-29.17%-36.09%IBIOiBio+6.02%+6.41%+35.61%-7.31%-54.32%IMUCEOM Pharmaceutical+14.10%-22.49%+2.81%-34.89%-58.82%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBCDABioCardia2.6066 of 5 stars3.82.00.00.01.12.50.6CUBTCurative BiotechnologyN/AN/AN/AN/AN/AN/AN/AN/AIBIOiBio2.2396 of 5 stars3.50.00.00.03.40.00.6IMUCEOM PharmaceuticalN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBCDABioCardia 3.50Strong Buy$25.001,143.78% UpsideCUBTCurative Biotechnology 0.00N/AN/AN/AIBIOiBio 3.00Buy$5.00509.01% UpsideIMUCEOM Pharmaceutical 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest IBIO, IMUC, CUBT, and BCDA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/25/2025IBIOiBioChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.00(Data available from 9/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBCDABioCardiaN/AN/AN/AN/A($0.33) per shareN/ACUBTCurative BiotechnologyN/AN/AN/AN/AN/AN/AIBIOiBio$375K43.03N/AN/A$1.41 per share0.58IMUCEOM PharmaceuticalN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBCDABioCardia-$7.95M-$1.85N/AN/AN/AN/A-19,117.42%-246.92%11/11/2025 (Estimated)CUBTCurative BiotechnologyN/AN/A0.00∞N/AN/AN/AN/AN/AIBIOiBio-$24.91MN/A0.00N/AN/AN/A-73.15%-45.51%N/AIMUCEOM Pharmaceutical-$1.89MN/A0.00∞N/AN/AN/AN/AN/ALatest IBIO, IMUC, CUBT, and BCDA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/11/2025Q2 2025BCDABioCardia-$0.50-$0.40+$0.10-$0.40N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBCDABioCardiaN/AN/AN/AN/AN/ACUBTCurative BiotechnologyN/AN/AN/AN/AN/AIBIOiBioN/AN/AN/AN/AN/AIMUCEOM PharmaceuticalN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBCDABioCardiaN/A0.330.33CUBTCurative BiotechnologyN/AN/AN/AIBIOiBio0.051.761.76IMUCEOM PharmaceuticalN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBCDABioCardia20.57%CUBTCurative BiotechnologyN/AIBIOiBio7.90%IMUCEOM PharmaceuticalN/AInsider OwnershipCompanyInsider OwnershipBCDABioCardia20.00%CUBTCurative BiotechnologyN/AIBIOiBio0.58%IMUCEOM Pharmaceutical3.28%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBCDABioCardia405.80 million4.64 millionOptionableCUBTCurative Biotechnology41.01 billionN/ANot OptionableIBIOiBio10019.66 million9.82 millionN/AIMUCEOM Pharmaceutical3126.50 million122.35 millionNot OptionableIBIO, IMUC, CUBT, and BCDA HeadlinesRecent News About These CompaniesQ32 Bio Inc. R (DB0.BE)January 15, 2025 | finance.yahoo.comImmunoCellular Therapeutics, Ltd. (IMUC)January 5, 2024 | uk.finance.yahoo.comEOM Pharmaceutical Holdings Inc.December 29, 2023 | wsj.comEOM Pharmaceutical Holdings Provides an Update on its Lead Drug Candidate EOM613November 7, 2023 | finance.yahoo.comAAO 2023: Apellis unveils data from GALE extension studyNovember 4, 2023 | ophthalmologytimes.comOIZERVAY™ (avacincaptad pegol intravitreal solution) Monthly or Every Other Month Reduced Geographic Atrophy Lesion Growth Through 2 YearsNovember 4, 2023 | markets.businessinsider.comImmunoGen (IMGN) Q3 Earnings Beat, Elahere Drives RevenuesNovember 3, 2023 | msn.comOramed Pharmaceuticals Inc ORMPNovember 1, 2023 | morningstar.comMAnalyst Ratings for Olema PharmaceuticalsOctober 11, 2023 | markets.businessinsider.comEOM Pharmaceutical Holdings Announces Topline Results of its COVID-19 Clinical Trial of EOM613 in BrazilSeptember 6, 2023 | finance.yahoo.comQ2 2023 PAVmed Inc Earnings CallAugust 17, 2023 | uk.finance.yahoo.comEOM Pharmaceuticals shelves plans to uplist shares, raise $15MAugust 3, 2023 | msn.comSYFOVRE® (pegcetacoplan injection) Continued to Demonstrate Increasing Treatment Effects Over ...July 30, 2023 | bakersfield.comBAcumen Pharmaceuticals Announces Proposed Public Offering of Common StockJuly 17, 2023 | benzinga.comFDA rejects Amneal's Parkinson's drugJuly 5, 2023 | beckershospitalreview.comBAmneal Pharmaceuticals: FDA Requests Additional Information on IPX203 IngredientJuly 3, 2023 | marketwatch.comBishop Rehabilitation & Nursing Names Their June 2023 EOMJune 26, 2023 | patch.comAmneal Pharmaceuticals Gets FDA Approval for Injectable Tumor TreatmentJune 14, 2023 | marketwatch.comTrade commission fights Amgen's $28B purchase of Horizon TherapeuticsMay 16, 2023 | msn.comOramed: Q1 Earnings SnapshotMay 12, 2023 | timesunion.comTNew MarketBeat Followers Over TimeMedia Sentiment Over TimeIBIO, IMUC, CUBT, and BCDA Company DescriptionsBioCardia NASDAQ:BCDA$2.01 -0.03 (-1.47%) As of 09:53 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia. The company is also developing an allogeneic cells therapy platform, which is an investigational culture expanded bone marrow derived mesenchymal cell therapy in Phase I/II trial to treat ischemic heart failure and acute respiratory distress syndrome. In addition, it offers the Helix biotherapeutic delivery system for minimally invasive targeted delivery of biologic agents to the heart; and Morph deflectable guides and sheaths. The company has collaboration agreements with CellProthera in the development of ProtheraCytes, which is currently under Phase II trial for the treatment of acute myocardial infarction. BioCardia, Inc. is based in Sunnyvale, California.Curative Biotechnology OTCMKTS:CUBT$0.0085 0.00 (-5.56%) As of 09/3/2025 02:15 PM EasternCurative Biotechnology, Inc., a development-stage biomedical company, focuses on novel treatments for rare diseases. The company focuses on therapies with potentially accelerated development paths as a result of the disease, the nature of the therapeutic itself, or the stage of clinical development. Its pipeline candidates include CURB906, an antibody-drug conjugate for targeting CD56 positive brain tumors; and IMT504, a novel immune therapy to treat rabies. The company has an agreement with Mid-Atlantic BioTherapeutics, Inc. to develop the COVID-19 vaccine. Curative Biotechnology, Inc. was founded in 1995 and is based in Boca Raton, Florida.iBio NYSE:IBIO$0.82 -0.04 (-4.40%) As of 10:02 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.iBio, Inc., a biotechnology company, engages in the development of precision antibodies in the United States. It offers IBIO-100, a preclinical anti-fibrotic program for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis; and EngageTx platform, which provides an optimized CD3 T-cell engager antibody panel. The company is also developing vaccine candidates, including IBIO-101, an antibody to reduce tumor growth; Endostatin E4 peptide for use in chemotherapy and immunotherapy; Trop-2 for the treatment Trop-2 positive cancers; MUC16, a tumor-associated epitope; anti-EGFRvIII antibody to treat glioblastoma and other cancers; CCR8 protein candidate for treatment of various cancers; PD-1 agonist for the treatment of rheumatoid arthritis and other inflammatory diseases; and IBIO-400 for the treatment of classical swine fever. iBio, Inc. has agreement with The Texas A&M University System for designing and manufacturing of plant-made biopharmaceuticals; and a research collaboration with the National Institute of Allergy and Infectious Diseases to investigate the potential of the company's AI-driven epitope steering platform for the development of a vaccine for Lassa fever. The company was incorporated in 2008 and is headquartered in Bryan, Texas.EOM Pharmaceutical OTCMKTS:IMUC$0.07 +0.01 (+14.10%) As of 09/3/2025 02:42 PM EasternImmunocellular Therapeutics, Ltd., a clinical-stage pharmaceutical company, focuses on the development of therapeutics and delivery technologies for the treatment of inflammatory conditions and ocular diseases. Its lead clinical asset is EOM613 solution, a peptide nucleic-acid solution with anti-inflammatory and pro-inflammatory effects on cytokines and chemokines for the treatment of cancer cachexia and rheumatoid arthritis. The company also develops EOM 147, an investigational, broad-spectrum aminosterol with an intracellular mechanism for the treatment of chronic and debilitating retinal diseases. Immunocellular Therapeutics, Ltd. was founded in 2020 and is headquartered in Montvale, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Zscaler Shares Can Hit a Fresh High Before Year-End Why Qualcomm Is Outperforming NVIDIA After Months of Lagging Alphabet Stock Surges After Dodging Harsh Antitrust Remedies Wall Street Punishes Dell's Record Quarter: Why They Are Wrong Ambarella's Earnings Prove Its Edge AI Strategy Is a Winner Taiwan Semiconductor Falls on China News—Buy The Dip? CrowdStrike Tests $412 Support as Options Traders Turn Bullish What to Expect From the Q3 Reporting Season Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
